

Meiji Seika Pharma Co., Ltd.

October 1, 2024

**Meiji Seika Pharma Submits Application to Amend Approval for KOSTAIVE®, a Self-Amplifying mRNA Vaccine against COVID-19, to Include Domestic Manufacturing Sites in Japan**

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it submitted an application for a partial amendment to the manufacturing and marketing approval of “KOSTAIVE® for Intramuscular Injection”, a self-amplifying mRNA vaccine for protection against COVID-19 including the Omicron subvariant JN.1, to include domestic manufacturing sites in Japan.

Meiji Seika Pharma has an exclusive partnership with CSL Seqirus for the distribution of KOSTAIVE® in Japan. In collaboration with ARCALIS Inc., Meiji Seika Pharma plans to start shipping domestically produced KOSTAIVE® in December 2024.

**About sa-mRNA**

mRNA vaccines help protect against infectious diseases by providing a blueprint for cells in the body to make a protein to help our immune systems recognize and fight the disease. Unlike standard mRNA vaccines, self-amplifying mRNA vaccines instruct the body to make more mRNA and protein to boost the immune response.